Currently set to Index
Currently set to Follow
search
ask age2b
CART 0

Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease

By AGE2B team
May 9, 2021
0
0

Akira Sezai 1, Satoshi Unosawa 1, Makoto Taoka 1, Shunji Osaka 1, Hisakuni Sekino 2, Masashi Tanaka 1

Main idea: Febuxostat had stronger renoprotective and antioxidant effects than topiroxostat in patients with hyperuricemia and chronic kidney disease.

Abstract

Background: The TROFEO trial demonstrated that febuxostat causes a greater and more rapid reduction of serum uric acid (s-UA) than topiroxostat. We compared these drugs in patients with chronic kidney disease (CKD) by sub-analysis of the TROFEO trial.

Methods: This sub-analysis targeted patients with an estimated glomerular filtration rate (eGFR) The primary endpoint was the s-UA level. Secondary endpoints included creatinine, eGFR, urinary albumin, cystatin-C, and oxidized low-density lipoprotein.

Results: There was no significant difference of s-UA between the two groups either before or after treatment. Serum creatinine (s-Cr) and eGFR were significantly better after 6 months of febuxostat treatment compared with topiroxostat. The Ox-LDL was significantly lower after 3 and 6 months.

Source NIH

Leave a Reply

Ask your question

We read all your emails and your text. Your question will be responded by our specialists, or one of the doctors we're working with, or our community

Please complete the required fields.